Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Noncanonical β-catenin interactions promote leukemia-initiating activity in early T-cell acute lymphoblastic leukemia

Patrizio Panelli, Elisabetta De Santis, Mattia Colucci, Francesco Tamiro, Francesca Sansico, Mattia Miroballo, Emanuele Murgo, Costanzo Padovano, Sam Gusscott, Michele Ciavarella, Elizabeth A. Chavez, Fabrizio Bianchi, Giovanni Rossi, Angelo M. Carella, Christian Steidl, Andrew P. Weng, Vincenzo Giambra

Blood (2023) 141 (13): 1597–1609.

https://doi.org/10.1182/blood.2022017079

Published: 2023

Includes: Supplemental data

Journal Articles

High Resolution Donor/Recipient HLA Matching Level in Unrelated Hematopoietic Stem Cell Transplantation and Impact on the Transplant Outcome: The Italian Experience on Behalf of GITMO, IBMDR and Aibt

Blood (2018) 132 (Supplement 1): 4642.

https://doi.org/10.1182/blood-2018-99-114486

Published: 2018

Journal Articles

Prophylaxis with ATLG Significantly Improves Chronic Graft-Versus-Host Disease / Relapse-Free Survival and Quality of Life after a Myeloablative HLA Identical Sibling Transplant for Acute Leukemia Patients in Complete Remission. Long-Term Follow-up of the Randomized ATG Familystudy

Blood (2017) 130 (Supplement 1): 519.

https://doi.org/10.1182/blood.V130.Suppl_1.519.519

Published: 2017

Journal Articles

Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA)

Blood (2016) 128 (22): 470.

https://doi.org/10.1182/blood.V128.22.470.470

Published: 2016

Journal Articles

The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

Craig H. Moskowitz, MD, Auayporn Nadamanee, MD, Tamas Masszi, MD PhD, Edward Agura, MD, Jerzy Holowiecki, MD PhD, Muneer H. Abidi, MD, Andy I Chen, MDPhD, Patrick J. Stiff, MD, Alessandro M. Gianni, MD, Angelo M. Carella, MD, Dzhelil Osmanov, MD, Veronika Bachanova, MD, John Sweetenham, MD, Anna Sureda, Dirk Huebner, MD, Emily K. Larsen, MS, Naomi N.H. Hunder, MD, Jan Walewski

Blood (2014) 124 (21): 673.

https://doi.org/10.1182/blood.V124.21.673.673

Published: 2014

Journal Articles

Panobinostat As Salvage Treatment for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible to High Dose Therapy: A Phase II Study of the Fondazione Italiana Linfomi (FIL)

Francesco Zaja, Stefano Volpetti, Annalisa Chiappella, MD, Flavia Salvi, MD, Angelo M. Carella, Adalberto Ibatici, Pier Paolo Piccaluga, Stefano A. Pileri, Davide Rossi, MD PhD, Pier Luigi Zinzani, Caterina Patti, Umberto Vitolo, Alfonso D'Arco, Alessandra Tucci, Silvia Franceschetti, Andrea Evangelista, Valentina Lenti, Renato Fanin, Alessandro Levis

Blood (2014) 124 (21): 1755.

https://doi.org/10.1182/blood.V124.21.1755.1755

Published: 2014

Journal Articles

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

Blood (2010) 116 (17): 3171–3179.

https://doi.org/10.1182/blood-2010-03-276196

Published: 2010

Journal Articles

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability

Blood (2010) 115 (18): 3671–3677.

https://doi.org/10.1182/blood-2009-12-253856

Published: 2010

Journal Articles

Non-Pegylated Lyposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Rituximab (R-COMP) as Initial Treatment for Patients with Splenic Marginal Zone Lymphoma (SMZL). A GISL Study

Emilio Iannitto, MD, Stefano Luminari, MD, Caterina Mammi, MD, Viviana Minardi, Francesco Merli, MD, Francesco Angrilli, MD, Caterina Stelitano, MD, Marina Cesaretti, Giovanni Franco, MD, Angelo M. Carella, MD, Massimo Federico, MD

Blood (2007) 110 (11): 1293.

https://doi.org/10.1182/blood.V110.11.1293.1293

Published: 2007

Journal Articles

Autologous Stem Cell Transplantation Followed by Reduced Intensity Allogeneic Stem Cell Transplantation (Tandem Transplantation) as Treatment for Advanced Resistant Hodgkin’s Lymphoma Patients. A Retrospective Analysis of the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT).

Ivan Alvarez, MD, Carme Canals, MD, Goli Taghipour, Angelo M. Carella, MD, PhD, Yves Beguin, MD, PhD, Didier Blaise, MD, PhD, Danielle Lazzlo, MD, PhD, Bernardino Aillone, MD, PhD, Jean H. Bourhis, MD, PhD, Lucca Castagna, MD, PhD, Paolo Corradini, MD, PhD, Paolo Iacopino, MD, PhD, Giuseppe Milone, MD, PhD, Pedro Pimentel, MD, PhD, Nigel H. Russell, MD, PhD, Pierre Zachee, MD, PhD, Anna Sureda, MD, PhD

Blood (2006) 108 (11): 3044.

https://doi.org/10.1182/blood.V108.11.3044.3044

Published: 2006

Journal Articles

Control of Residual Disease in Imatinib Treated Chronic Myeloid Leukemia Patients with Peptide Vaccinations: 2 Years Follow up of CMLVAX100 Trial.

Monica Bocchia, MD, Elisabetta Abruzzese, MD, Micaela Ippoliti, PhD, Maria Teresa Pirrotta, MD, Malgorzata M. Trawinska, MD, Marilina Amabile, PhD, Giovanni Martinelli, MD, Francesco Forconi, MD, Alessandro Gozzetti, MD, Angelo M. Carella, MD, Donatella Raspadori, PhD, Francesco Lauria, MD

Blood (2005) 106 (11): 167.

https://doi.org/10.1182/blood.V106.11.167.167

Published: 2005

Journal Articles

Autografting With Philadelphia Chromosome–Negative Mobilized Hematopoietic Progenitor Cells in Chronic Myelogenous Leukemia

Angelo M. Carella, Enrica Lerma, Maria T. Corsetti, Anna Dejana, Palmina Basta, Franca Vassallo, Monica Abate, Monica Soracco, Federica Benvenuto, Osvaldo Figari, Marina Podestà, Giovanna Piaggio, Raimondo Ferrara, Mario Sessarego, Caterina Parodi, Michele Pizzuti, Alessandra Rubagotti, Domenico Occhini, Francesco Frassoni

Blood (1999) 93 (5): 1534–1539.

https://doi.org/10.1182/blood.V93.5.1534

Published: 1999

NARROW

Noncanonical β-catenin interactions promote leukemia-initiating activity in early T-cell acute lymphoblastic leukemia

High Resolution Donor/Recipient HLA Matching Level in Unrelated Hematopoietic Stem Cell Transplantation and Impact on the Transplant Outcome: The Italian Experience on Behalf of GITMO, IBMDR and Aibt

Prophylaxis with ATLG Significantly Improves Chronic Graft-Versus-Host Disease / Relapse-Free Survival and Quality of Life after a Myeloablative HLA Identical Sibling Transplant for Acute Leukemia Patients in Complete Remission. Long-Term Follow-up of the Randomized ATG Familystudy

Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA)

The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

Panobinostat As Salvage Treatment for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible to High Dose Therapy: A Phase II Study of the Fondazione Italiana Linfomi (FIL)

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability

Non-Pegylated Lyposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Rituximab (R-COMP) as Initial Treatment for Patients with Splenic Marginal Zone Lymphoma (SMZL). A GISL Study

Control of Residual Disease in Imatinib Treated Chronic Myeloid Leukemia Patients with Peptide Vaccinations: 2 Years Follow up of CMLVAX100 Trial.

Autografting With Philadelphia Chromosome–Negative Mobilized Hematopoietic Progenitor Cells in Chronic Myelogenous Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only